Antibacterial Agents TRIZ Cases

Divided gepotidacin dosing maintains therapeutic levels to treat resistant Neisseria gonorrhoeae while minimizing safety risks.

Formula I and II compounds maintain inhibition activity in plasma, overcoming MCC950 instability.

OppA polypeptides resolve vaccine cross-protection gaps by targeting conserved antigens across diverse strains.

Antibodies bind human interleukin 2 to modulate receptor chains, reducing side effects while enhancing clinical efficacy in cancer treatment.

Engineered CDR regions boost neutralizing activity against PcrV, resolving low efficacy of conventional antibodies for treating resistant infections.

Formulating aerosolized fluoroquinolones with magnesium, calcium, or zinc increases lung sputum concentrations to treat resistant bacterial infections.

Titration controls pH to resolve contradictions between manufacturing precision and color stability in cefadroxil crystallization.

Multiple polymorphs of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide resolve trade-offs between production yield and physical stability.

Segmenting the vaccine into modular synthetic saccharides and universal CRM197 carriers expands serotype coverage while lowering manufacturing costs.

A benefit agent particle uses a core, shell, and polymer coating to deliver active ingredients.

Topical polyclonal antibodies inhibit Staphylococcus proliferation via epitope binding, avoiding antibiotic resistance and systemic side effects.

Extraction of epipyrone A from Epicoccum purpurascens provides effective antifungal activity against Botrytis cinerea while reducing environmental toxicity.

Schiff base synthesis of aromatic radical compounds reduces in vivo toxicity while maintaining antimicrobial activity against resistant strains.

Recombinant human antibodies target Acinetobacter antigens to overcome antibiotic resistance through enhanced opsonophagocytosis and therapeutic efficacy.

Propargyl-linked pyrimidine derivatives target dihydrofolate reductase to overcome resistance and side effects in anthrax and toxoplasmosis treatments.

Conjugating myristic acid to leptin peptides reduces plasma clearance and overcomes short serum half-life, enabling lower effective doses.

Isolated immunoglobulin heavy and light chain polypeptides bind programmed death-1 protein through specific complementarity determining region amino acid sequences.

Phage display isolates conserved protein fragments to overcome limited serotype coverage and antibiotic resistance in pneumococcal vaccines.

HJ-specific nucleases cleave Holliday junction structures within bacterial biofilms to disrupt their protective extracellular polymeric substance lattice.

Sulfur-containing adjuvant compounds amplify antibiotic activity to overcome bacterial resistance and reduce toxic side effects.

SVA-PEG conjugation stabilizes hemoglobin tetramers and reduces nitric oxide scavenging, resolving vasoconstriction while maintaining effective oxygen delivery.

Administering a biofilm dissolving agent removes colonic fecal material and disrupts biofilms to enhance microbial engraftment success rates.

Isolated SV2C luminal domain polypeptide binds the HC fragment of botulinum neurotoxin A to block receptor interaction.

An ApoA-IL15 fusion protein extends plasma half-life and reduces administration frequency while improving antitumor efficacy.

Expression vectors encoding Cj0998c, Cj0588, and Cj0248 proteins elicit immune responses that reduce Campylobacter jejuni colonization in poultry.

Aqueous doxycycline metal complex precipitation and drying yield stable solid tablets avoiding esophageal ulceration.

Precipitated manganese colloid resolves the contradiction between high immune enhancement efficacy and solution stability by preventing precipitation.

Dried microbial preparations incorporate buffering agents with pKa above 4.3 to neutralize acid and protect bacterial viability in vaginal environments.

Flagellin activates TLR5 signaling to recruit neutrophils, resolving drug resistance in refractory respiratory infections.

Ricinic acid oligomers replace toxic solvents with water-miscible alternatives, enabling controlled drug release while preventing initial bursts.

Computational design of engineered antimicrobial peptides with optimized hydrophobicity combats antibiotic-resistant infections.

Nifuratel overcomes bacterial vaginosis treatment failures by targeting resistant Atopobium species with lower minimum inhibitory concentrations.

Tris buffer raises finafloxacin solubility and stability, preventing particle formation in high-concentration parenteral solutions.

Targeting conserved virulence factors replaces broad-spectrum vaccines to resolve partial protection gaps against necrotic enteritis strains.

Hyperactive PlyGBS mutant lysins enzymatically degrade peptidoglycan cell walls, reducing colonization and avoiding antibiotic resistance.

Anti-interleukin-33 antibodies target cytokine binding to resolve the lack of effective antagonists for allergy-related disorders.

Nanoscaling clobetasol propionate prevents precipitation in oil-free aqueous suspensions, maintaining long-term transparency and reducing ocular irritation.

Combining protein A and Sbi domains overcomes limited vaccine efficacy by targeting bacterial defense mechanisms while maintaining manufacturing feasibility.

Imatinib kinase inhibitor reduces bacterial loads and granulomatous lesions to manage multiple drug-resistant tuberculosis infections.

Sn-2 monoacylglycerol derivatives deliver bioactive fatty acids directly to the intestine without requiring digestion.

Linalool and hinokitiol in a cleanser formulation reduce microbial colonization on the eyelid while preventing skin irritation.

Linking quinolone and oxazolidinone pharmacophores into one molecule overcomes multi-drug resistant bacteria while simplifying treatment protocols.

A single-dose vaccine combines inactivated Erysipelothrix rhusiopathiae and Haemophilus parasuis antigens with a mineral oil adjuvant.

Glyceryl tripropionate balances gut flora to inhibit Clostridium perfringens, resolving antibiotic ban compliance while maintaining disease prevention.

Genetically modified Pasteurella multocida strains overexpress iron-regulated outer membrane proteins to enhance vaccine immunogenicity.

Hydroxyflavanones reduce bitter taste impressions without suppressing sweet taste, avoiding waste from stressful extraction treatments.

Bacillus clausii lantibiotic peptides overcome pathogen resistance via lanthionine bridges and biosynthetic self-service.